Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    COVID-19 Industry Rivals Plan Joint Pledge on Vaccine Safety

    By Global Biodefense StaffSeptember 4, 2020
    Specimen tray sitting in the biological safety cabinet, known as the ‘hood’, for COVID-19 testing. Credit: Amanda Wagner
    Share
    Facebook LinkedIn Reddit Email

    Several drug makers developing vaccines to counter SARS-CoV-2 plan to issue a public pledge not to seek government approval until the shots have proven to be safe and effective, an unusual joint move among rivals that comes as they work to address concerns over a rush to mass vaccination.

    A draft of the joint statement, still being finalized by companies including Pfizer Inc., Johnson & Johnson and Moderna Inc., is expected this week.

    Senior regulators at the FDA have also been discussing making their own public statement about the need to rely on proven science.

    On Monday, AstraZeneca’s CEO released a statement acknowledging recent questions about the speed of vaccine development. And on Friday, Moderna’s chief executive, Stéphane Bancel, told CNBC that the company was slowing enrollment in its trials to include more people from groups at high risk for Covid-19

    Pfizer Chief Executive Albert Bourla said the company expects to have enough data in October to file for an emergency-use authorization if the study results are positive. For Pfizer and Moderna’s vaccines, subjects must return several weeks later to get a second dose, leaving just a few weeks of evaluation for even the first subjects enrolled for a coming regulatory filing.

    Read the full story at The New York Times and The Wall Street Journal.

    COVID-19 Drug Development Editor Pick SARS-CoV-2 Vaccine News Vaccine Opposition
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleThe Challenge of Vaccine Cold Chain Logistics: How a Chemical ‘Casing’ Could Save Lives
    Next Article Declining Antibodies and Immunity to COVID-19 – Why the Worry?

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy